Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
- PMID: 34079068
- PMCID: PMC8960395
- DOI: 10.1038/s41380-021-01161-7
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
Abstract
Promotion of good mental health, prevention, and early intervention before/at the onset of mental disorders improve outcomes. However, the range and peak ages at onset for mental disorders are not fully established. To provide robust, global epidemiological estimates of age at onset for mental disorders, we conducted a PRISMA/MOOSE-compliant systematic review with meta-analysis of birth cohort/cross-sectional/cohort studies, representative of the general population, reporting age at onset for any ICD/DSM-mental disorders, identified in PubMed/Web of Science (up to 16/05/2020) (PROSPERO:CRD42019143015). Co-primary outcomes were the proportion of individuals with onset of mental disorders before age 14, 18, 25, and peak age at onset, for any mental disorder and across International Classification of Diseases 11 diagnostic blocks. Median age at onset of specific disorders was additionally investigated. Across 192 studies (n = 708,561) included, the proportion of individuals with onset of any mental disorders before the ages of 14, 18, 25 were 34.6%, 48.4%, 62.5%, and peak age was 14.5 years (k = 14, median = 18, interquartile range (IQR) = 11-34). For diagnostic blocks, the proportion of individuals with onset of disorder before the age of 14, 18, 25 and peak age were as follows: neurodevelopmental disorders: 61.5%, 83.2%, 95.8%, 5.5 years (k = 21, median=12, IQR = 7-16), anxiety/fear-related disorders: 38.1%, 51.8%, 73.3%, 5.5 years (k = 73, median = 17, IQR = 9-25), obsessive-compulsive/related disorders: 24.6%, 45.1%, 64.0%, 14.5 years (k = 20, median = 19, IQR = 14-29), feeding/eating disorders/problems: 15.8%, 48.1%, 82.4%, 15.5 years (k = 11, median = 18, IQR = 15-23), conditions specifically associated with stress disorders: 16.9%, 27.6%, 43.1%, 15.5 years (k = 16, median = 30, IQR = 17-48), substance use disorders/addictive behaviours: 2.9%, 15.2%, 48.8%, 19.5 years (k = 58, median = 25, IQR = 20-41), schizophrenia-spectrum disorders/primary psychotic states: 3%, 12.3%, 47.8%, 20.5 years (k = 36, median = 25, IQR = 20-34), personality disorders/related traits: 1.9%, 9.6%, 47.7%, 20.5 years (k = 6, median = 25, IQR = 20-33), and mood disorders: 2.5%, 11.5%, 34.5%, 20.5 years (k = 79, median = 31, IQR = 21-46). No significant difference emerged by sex, or definition of age of onset. Median age at onset for specific mental disorders mapped on a time continuum, from phobias/separation anxiety/autism spectrum disorder/attention deficit hyperactivity disorder/social anxiety (8-13 years) to anorexia nervosa/bulimia nervosa/obsessive-compulsive/binge eating/cannabis use disorders (17-22 years), followed by schizophrenia, personality, panic and alcohol use disorders (25-27 years), and finally post-traumatic/depressive/generalized anxiety/bipolar/acute and transient psychotic disorders (30-35 years), with overlap among groups and no significant clustering. These results inform the timing of good mental health promotion/preventive/early intervention, updating the current mental health system structured around a child/adult service schism at age 18.
© 2021. The Author(s).
Conflict of interest statement
MS has been a consultant and/or advisor to or has received honoraria from Angelini, Lundbeck. CUC has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. PF-P has received grant fees from Lundbeck and honoraria from Lundbeck, Menarini and Angelini, outside the current work. All other authors declare no conflict of interest.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8960395/bin/41380_2021_1161_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8960395/bin/41380_2021_1161_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8960395/bin/41380_2021_1161_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8960395/bin/41380_2021_1161_Fig4_HTML.gif)
Similar articles
-
Early age of onset of mood, anxiety and alcohol use disorders is associated with sociodemographic characteristics and health outcomes in adults: results from a cross-sectional national survey.Soc Psychiatry Psychiatr Epidemiol. 2021 Oct;56(10):1835-1846. doi: 10.1007/s00127-021-02070-4. Epub 2021 Mar 31. Soc Psychiatry Psychiatr Epidemiol. 2021. PMID: 33791821
-
Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment.Mol Psychiatry. 2023 Jun;28(6):2291-2300. doi: 10.1038/s41380-023-02029-8. Epub 2023 Jun 9. Mol Psychiatry. 2023. PMID: 37296309 Free PMC article.
-
Body dysmorphic disorder in patients with obsessive-compulsive disorder: prevalence and clinical correlates.Depress Anxiety. 2012 Nov;29(11):966-75. doi: 10.1002/da.21980. Epub 2012 Jul 19. Depress Anxiety. 2012. PMID: 22815241
-
Prevalence of psychiatric co-morbidity in treatment-seeking problem gamblers: A systematic review and meta-analysis.Aust N Z J Psychiatry. 2015 Jun;49(6):519-39. doi: 10.1177/0004867415575774. Epub 2015 Mar 3. Aust N Z J Psychiatry. 2015. PMID: 25735959 Free PMC article. Review.
-
The prevalence of autism spectrum disorder traits and diagnosis in adults and young people with personality disorders: A systematic review.Aust N Z J Psychiatry. 2023 Feb;57(2):181-196. doi: 10.1177/00048674221114603. Epub 2022 Aug 19. Aust N Z J Psychiatry. 2023. PMID: 35986511 Free PMC article. Review.
Cited by
-
Maintaining disorder: estimating the association between policing and psychiatric hospitalization among youth in New York City by neighborhood racial composition, 2006-2014.Soc Psychiatry Psychiatr Epidemiol. 2024 Aug 1. doi: 10.1007/s00127-024-02738-7. Online ahead of print. Soc Psychiatry Psychiatr Epidemiol. 2024. PMID: 39088094
-
Inflammatory Hematological Ratios in Adolescents with Mental Disorders: A Scoping Review.Consort Psychiatr. 2024 Jul 6;5(2):45-61. doi: 10.17816/CP15514. eCollection 2024. Consort Psychiatr. 2024. PMID: 39071999 Free PMC article. Review.
-
Association between Depressive Symptoms, Physical Activity, and Health Factors in Hispanic Emerging Adults.Int J Environ Res Public Health. 2024 Jul 14;21(7):918. doi: 10.3390/ijerph21070918. Int J Environ Res Public Health. 2024. PMID: 39063494 Free PMC article.
-
Prevalence of Specific Mood Profile Clusters among Elite and Youth Athletes at a Brazilian Sports Club.Sports (Basel). 2024 Jul 18;12(7):195. doi: 10.3390/sports12070195. Sports (Basel). 2024. PMID: 39058086 Free PMC article.
-
Leucine-rich Glioma Inactivated 1 (LGI-1) Limbic Encephalitis Presenting with Psychotic Symptoms without Seizures: A Case Report with Five-year Follow-up and Review of Literature.Indian J Psychol Med. 2024 Jul;46(4):367-370. doi: 10.1177/02537176231226191. Epub 2024 Feb 11. Indian J Psychol Med. 2024. PMID: 39056044 Free PMC article. No abstract available.
References
-
- Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4:295–301. - PubMed
-
- Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–31. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical